Lyon, December 6th, 2018
BIOASTER, the French Technology Research Institute for Microbiology and Infectious Diseases, today announced the initiation of a collaborative program with BIOASTER, BioRad Laboratories, Inc. and Genetic Analysis aimed at evaluating microbial dysbiosis signatures in the field of metabolic disorders.
This project is a unique opportunity for BIOASTER to capitalize on its breakthrough deep and 16S-targeted sequencing technologies and advanced pipelines of data analysis for highlighting new gut microbiome biomarkers of medical added value.
Endocrine and metabolic diseases are among the most common contemporary human afflictions in western countries and particularly in the United States. The high prevalence and incidence of common metabolic disorders such as diabetes and obesity have been confirmed through large population-based studies. Moreover, an increasing number of studies show that deregulation of gut microbiota composition (“dysbiosis”) is associated with onset of metabolic diseases and may impact treatment.
This original collaboration between Bio-Rad, a world leading provider of life science research and clinical diagnostic products, Genetic Analysis, a Norwegian company renowned in microbiome molecular diagnostics and BIOASTER will add an innovative edge of this research program by examining gut microbiota signatures for diagnostics. Genetic Analysis and Bio-Rad previously announced in December 2017 a supply and distribution agreement for Genetic Analysis’s GA-map™ clinical test for gut dysbiosis.
“This collaborative program illustrates very well BIOASTER’s ambition: bringing together multiple partners and complementary expertise for accelerating innovation towards industrial product development,” said Nathalie Garçon, CEO & CSO of BIOASTER. “We are very proud to be part of this exciting project that will generate new avenues in the field of the microbiomebased diagnostics.”
“We are delighted to collaborate with BIOASTER and Bio-Rad on this important research project” commented Ronny Hermansen, CEO of Genetic Analysis. “As more and more links are discovered between the human microbiome and immune status, the need for accurate biomarker-based tests becomes pressing. Genetic Analysis and Bio-Rad have a strong track record along with considerable experience in developing and bringing innovative diagnostic tools to market. We look forward to working with BIOASTER on this very interesting project”, he added.
BIOASTER is an independent non-profit organisation and one of the 8 French Technological Research Institutes (TRI). It was created in 2012 thanks to the joined efforts of the Paris Institut Pasteur and the Lyonbiopôle competitive cluster.
These original founders were joined at the start by the CEA, the CNRS, INSERM, Danone Nutricia Research, Institut Mérieux and Sanofi Pasteur and later in 2018 by bioMérieux. BIOASTER also benefits from the support of the French government through the Programme Investissements d’Avenir (Investing for the Future program, PIA), of Région Auvergne-RhôneAlpes and Métropole du Grand Lyon.
In the field of microbiology, BIOASTER develops and implements technological and transformative innovations, which speed up the development of new public health solutions and personalised medicine solutions.
BIOASTER is involved in four main application fields:
•Antimicrobials: to identify new medical candidates, to fight antimicrobials resistance
•Vaccines: to improve vaccines safety and efficacy
•Microbiota: to take full advantage of human and animal microbiota
•Diagnostic: to quickly diagnose infections at patient bedside
In each of these fields, our goal is to turn industrial needs into research projects dedicated to solutions and leveraging discoveries from academic research. BIOASTER thus develops a collaborative, multi-disciplinary and technologically integrated approach, to promote open innovation.
• interconnected state of the art technology units to serve 4 major programs: diagnostics / vaccines / antimicrobials / microbiota
• 2450m2 laboratories BSL 2 & 3 (LYON & PARIS)
• 120 people, including 80% of scientific experts, 18 different citizenships
• 54 projects including 27 with private partners 25 with public partners and 10 international & european projects.
About Genetic Analysis
Genetic Analysis (GA) is a Norwegian based molecular in vitro diagnostic company with core competence in mapping of microbiota, utilizing the GA-map® technology to develop IVD tests in diseases where microbiota is involved. The GA-map® Dysbiosis Test is the first documented CE marked routine test available to diagnose and characterize dysbiosis, initially targeted at IBS and IBD.
The test is an aide in diagnosis of diseases associated with dysbiosis and imbalances in the bacteria community in the digestive system. GA is developing innovative solutions for improved patient treatment in rapidly growing markets, with few diagnostic options. The company markets the GA-map® products to three market segments: medical routine diagnostics, clinical research and as companion diagnostics. GA has 21 employees, is located in Oslo and constitute a full value chain including R&D, manufacturing, and an in-house reference laboratory for external sample testing and reporting.
Comments are closed.